Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them
Ashgate Publishing, Ltd., 28.05.2015 - 234 Seiten
The second edition of Forecasting for the Pharmaceutical Industry continues to be a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making. The author explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches. The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars.
Was andere dazu sagen - Rezension schreiben
Es wurden keine Rezensionen gefunden.
The Past and the Present
The Forecasting Process
New Product Forecasting
InMarket Product Forecasting
Specialized Topics in Pharmaceutical Forecasting
Thoughts for the Future
PharmaCo A Forecasting Case Study
Andere Ausgaben - Alle anzeigen
Forecasting for the Pharmaceutical Industry: Models for New Product and In ...
Mr Arthur G Cook
Eingeschränkte Leseprobe - 2015
adalimumab adoption curves analysis approach assumptions biosimilar cannibalization Chizophrin compliance and persistence Cytoflux days of therapy decision makers demand sales diagnosed patients distributor dosing Drug Treated Patients drug treatment rate effects epidemiology erosion estimate European Medicines Agency european Union ex-factory sales ex-trend events example Exhibit filgrastim Focalitine forecast algorithm forecast model forecaster needs formulation founder effects future Gastroesophageal reflux disease historical data in-market insulin aspart intervention triangle launch line extension listromycin manufacturer market research market share Market TRx marketing intervention methodology methods number of patients original biologic medicine orphan drugs parallel importation patient share patient-based Patients millions Patients thousands pharmaceutical industry PharmaCo physician polypharmacy potential prescription Product 3 Product product forecasting Question rare diseases reimbursement revenue risk rituxan Sales millions scenarios schizophrenia Schizophrenia Market segmentation share Calculated shown in Figure spreadsheet Steadertin strategies substitution and interchangeability Table therapy area trend TRx millions uncertainty uptake variables